NCT07752108: A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis
- State
- Not started
- Phase
- Phase 3
- People
- 40 planned
- Started
- 16 Nov 2026
- Primary completion
- 30 May 2027
- Arms
- Part 1: Zasocitinib 30 mg, Part 2: Zasocitinib 30 mg, Optional Long-Term Extension (LTE): Zasocitinib
- Results
- None posted
- 7 Aug 2026: Trial registered